George Clinical – CRO China

George Clinical in China

China is George Clinical’s largest hub outside the head office of Sydney, offering full CRO services and a site network that spans the country.

With its immense potential for patient recruitment and a rapidly growing pharmaceutical market, China, currently the third largest in the world, is an obvious choice for many when entering the Asian market.

The Chinese healthcare delivery system consists of public hospitals and community healthcare centers, with an increasing private care system. Only GCP accredited sites are eligible for running commercial Phase I, II and III studies, and this accreditation can only be achieved by public hospitals in China. The accreditation is issued by the CFDA and NHPFC based upon a site inspection. Accreditation is renewed every 3 years, with a quality review performed by the PFDA every year.

George Clinical has an extensive network of over 260 trial centers in 50 cities for Phase II-IV trials, and a wider network that includes community health centers in semi-urban and rural areas for Phase IV trials.

What are the benefits of conducting clinical trials in China?

  • China has access to a large patient pool
  • Rapidly developing medical infrastructure in urban centres and centres of excellence for many common diseases such as hypertension, diabetes and renal disease
  • Low operational costs

What are the prevalent diseases in China?

  1. Stroke
  2. Ischaemic Heart Disease
  3. Chronic obstructive pulmonary disease
  4. Cancer
  5. Road injury
  6. Hypertension
  7. Diabetes mellitus
  8. Lower respiratory infections

George Clinical China News

乔治全球健康研究院与中国疾控中心慢病中心正式签署合作谅解备忘录

2017年2月9日,中国北京。乔治全球健康研究院与中国疾控中心慢病中心正式签署了合作谅解备忘录(MOU)。

TGI signed MOU with NCNCD, China CDC

BEIJING – February 9, 2017– The Memorandum of Understanding (MOU) was signed between The George Institute for Global Health (TGI) and National Center for Chronic and Non-Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention (NCNCD...

最新柳叶刀文章 – 超低剂量联合用药或成为控制高血压的有效途径

乔治全球健康研究院最新试验表明,超低剂量多效药片或成为控制高血压的有效途径。该试验具有重要的临床意义,每位受试者的血压都在四周内降至正常水平。该研究项目由澳大利亚国家心脏基金会和悉尼大学赞助,其成果已发表于柳叶刀期刊。

Potential breakthrough for helping to reduce the burden of hypertension

A small but clinically important trial of a new ultra low-dose four-in-one pill to treat high blood pressure has produced remarkable results.

抗炎药无助于缓解腰背疼痛

乔治全球健康研究院最新研究表明, 抗炎类药物无助于缓解腰背疼痛, 反而具有副作用。

The drugs provide little benefit, says back pain researchers

Commonly used non-steroidal anti-inflammatory drugs used to treat back pain provide little benefit, but cause side effects, according to new research from The George Institute for Global Health.

Contact

George Clinical Address:
Level 18, Tower B, Horizon Tower
Haidian District
Beijing, 100088
P.R. China

2223, 22/F Tomson Commercial Building,
710 Dongfang Road, Pudong District
Shanghai, 200122
P.R. China

Details

Number of Personnel: 50
In-country Services:

Beijing
Project Management, Clinical Operations, Data Management, Medical and Safety Services, Clinical Compliance, Regulatory Services, Statistics, Health Economics

Shanghai
Clinical Operations

Chengdu
Clinical Operations

Harbin
Project Management, Clinical Operations

Population:1.4 billion
Official Language:Putonghua (Mandarin). Local dialects may be used
Hospital Records Language:Simplified Chinese
Electronic Hospital Records:Currently, paper records are used.

Twitter Facebook LinkedIn